Arachidonic Acid News and Research

RSS

Arachidonic acid is an omega-6 fatty acid that is present in the phospholipids (especially phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositides) of membranes of the body's cells, and is abundant in the brain. It is the counterpart to the saturated arachidic acid found in peanut oil.

Researchers map processes that power health benefits of omega-3 fatty acids

For the first time, researchers at the University of California, San Diego have peered inside a living mouse cell and mapped the processes that power the celebrated health benefits of omega-3 fatty acids. More profoundly, they say their findings suggest it may be possible to manipulate these processes to short-circuit inflammation before it begins, or at least help to resolve inflammation before it becomes detrimental.

16 May 2012

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

New imaging tool reveals subtle changes in breast tissue

Purdue University researchers have created a new imaging technology that reveals subtle changes in breast tissue, representing a potential tool to determine a woman's risk of developing breast cancer and to study ways of preventing the disease.

6 Mar 2012

Study refutes perinatal programming theory about adipose tissue growth

Is obesity in infants "programmed" in the womb? Previously, researchers assumed that consumption of "bad" fats during pregnancy contribute to excessive infant adipose tissue growth and that "good" omega-3 fatty acids prevent expansive adipose tissue development. A study run by the Technische Universit-t M-nchen showed no evidence to support this "perinatal programming" theory.

5 Jan 2012

New metabolic pathway for controlling brain inflammation

A team led by scientists from The Scripps Research Institute has identified a new metabolic pathway for controlling brain inflammation, suggesting strategies for treating it.

21 Oct 2011

New insights into actions of NSAIDs

Ibuprofen, naproxen, and related non-steroidal anti-inflammatory drugs (NSAIDs) - the subjects of years of study - still have some secrets to reveal about how they work.

26 Sep 2011

Infant formulas fortified with LCPUFA are good for developing brains and hearts

University of Kansas scientists have found new evidence that infant formulas fortified with long chain polyunsaturated fatty acids (LCPUFA) are good for developing brains and hearts.

20 Sep 2011

Omega-3s decreases severity of brain damage after stroke

A diet rich in omega-3s reduces the severity of brain damage after a stroke, according to a study conducted by Universit- Laval researchers. The team, co-directed by professors Jasna Kriz and Fr-d-ric Calon, showed that the extent of brain damage following a stroke was reduced by 25% in mice that consumed DHA type omega-3s daily.

26 Aug 2011

Research reveals how humans of different ancestry process polyunsaturated fat

Over the past decade, much progress has been made regarding the understanding and promise of personalized medicine. Scientists are just beginning to consider the impact of gene-diet interactions in different populations in regards to disease prevention and treatment.

15 Jun 2011

Researchers discover new avenue for hypertension, cardiovascular disease treatment

More than one-third of the world's population suffers from hypertension and cardiovascular disease. The U.S. Agency for Healthcare Quality and Research has reported that Americans spent $29 billion for non-prescription cardiovascular drugs alone in 2008.

11 Apr 2011

Orexo partner ProStrakan launches Abstral in the US

Orexo AB announces today that its partner ProStrakan Group plc has launched Abstral in the United States.

4 Apr 2011

Positive outcome from Orexo's OX51 initial pharmacokinetic trial to treat acute intensive pain

Orexo AB announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief.

1 Apr 2011

Health Canada approves Orexo's Abstral to treat chronic cancer pain

Orexo AB today announces that ProStrakan's partner, Paladin Labs Inc. has been informed by Health Canada, the Canadian Government Department with responsibility for public health, that it has approved Abstral.

22 Feb 2011

Orexo fourth quarter net revenues increase to MSEK 109.1

Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.

16 Feb 2011

Orexo, Invida enter exclusive licensing and distribution agreement for Abstral in Asia Pacific

Orexo AB and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo's product for the treatment of breakthrough cancer pain.

14 Jan 2011

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

14 Jan 2011

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Royal DSM to acquire Martek for $1,087 million

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.

21 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."

15 Dec 2010